Each patient received at least two intratumoral quadrivalent HPV-L1 vaccine (GardasilTM) injections and daily topical TLR-7 agonist (imiquimod) to the tumor surface 2 weeks apart. The gene discussed is TLR7; the disease is neoplasm.